Bright Future Suspected For Pfizer Cancer Drug, Ibrance
Positive result come out of Ibrance's Phase 3 PALOMA-2 trial and is now expected to make huge profit for Pfizer in the future.
Pfizer Incorporation's cancer treatment drug, Ibrance got positive results out of Phase 3 PALOMA-2 trial, the announcement on Tuesday. Ibrance is an oral first in class inhibitor of cyclin-dependent kinases 4 and 6. The study showed that this drug when taken with letrozole for menopause in women with estrogen receptor positive, human epidermal growth factor receptor 2-negative and breast cancer proved to work quite well.
The medicinal company drug once taken showed improvement in PFS in comparison to the placebos these women consumed. Ibrance has already been approved by the Food and Drug Administration which in 2015, February which were based on the PALOMA-1 clinical trial . Now that the second trial has proved to be successful an approval for this is soon to come from the FDA. Pfizer Inc. hopes to gather more safety data and other information regarding the drug and later demonstrate it at the yearly meeting of American Society of Clinical Oncology.
The pharmaceutical company is expecting more information to come from the third trial of this drug that will help it get more approvals and certifications internationally and a complete approval in the United States. The investors were already pleased when the drug received the approval of the FDA and now are even more satisfied since the second clinical trial was a success. Ibrance was given approval in combination with Femara for breast cancer and postmenopausal women.
Ibrance has so far been going strong in terms of profits, approvals and clinical test, thus it will be soon seen more often in the market. Pfizer hopes attain not just approvals and marketing in the US but even Europe, it has already submitted an MAA(Marketing Authorization Application) to the European Medicines Agency, which was done in 2015, August. The recent development might help pace things up to get this approval.
According to the senior vice president of global product development of the pharma giant, Ibrance is the only CDK 4?6 inhibitor which has the phase 3 data in breast cancer and is the only drug approved so far in this category. This drug has even managed to show survival rates getting higher in patients who are diagnosed with breast cancer. Another drug might come up in the future that is going to compete with Ibrance, called abemaciclib made by Eli Lilly and Co.’s . However it is pending the approval of the FDA and is currently under review. Ibrance is a step ahead of its competitor so far and things are happening rapidly.
The US drug maker expects this drug to get it a huge amount of profit and is expecting it to become the company's major growth driver and sees strong potential in this product. The CEO of the medicinal giant, Ian Read said at the fourth quarter earning call, "We expect to deliver operational revenue growth in 2016. Our key growth drivers will continue to be Ibrance, Eliquis, and Xeljanz.”
